Abstract: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.
Type:
Application
Filed:
September 6, 2013
Publication date:
December 26, 2013
Applicants:
INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPE
Inventors:
John J. ROSSI, Mark A. BEHLKE, Dongho KIM
Abstract: The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.
Type:
Application
Filed:
February 25, 2013
Publication date:
September 12, 2013
Applicant:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Mark Aaron Behlke, Kimberly Ann Lennox, Ashley Mae Jacobi, Richard Owczarzy, Joseph Alan Walder
Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.
Abstract: The invention provides compositions and methods for amplifying nucleic acid polymer sequences in a high complexity nucleic acid sample. The unique compositions of the invention include a primer set composed of a mixture of two types of primers for DNA synthesis. For extension in one direction, the primers all contain modifications that destroy their ability to serve as templates that can be copied by DNA polymerases. For extension in the opposite direction the set includes at least one primer that can serve as a template and be replicated by DNA polymerases throughout its length. The method can be carried out by mixing the nucleic acid polymer sequence of interest with the set of DNA synthesis primers in an amplification reaction mixture. The reaction mixture is then subjected to temperature cycling analogous to the temperature cycling in PCR reactions. At least one primer in the primer set hybridizes to the nucleic acid polymer.
Type:
Grant
Filed:
September 9, 2009
Date of Patent:
March 19, 2013
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Mark Aaron Behlke, Joseph Alan Walder, Jeffrey A. Manthey
Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.
Type:
Grant
Filed:
November 17, 2011
Date of Patent:
February 19, 2013
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Andrei Laikhter, Mark Aaron Behlke, Joseph Walder, Kevin William Roberts, Yawfui Yong
Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
Type:
Application
Filed:
June 8, 2012
Publication date:
October 11, 2012
Applicants:
INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPE
Inventors:
John J. ROSSI, Mark A. BEHLKE, Dongho KIM
Abstract: A compound having the general formula shown below: where R1-6 are independently selected from the group consisting of an electron withdrawing group, an alkyl group, an aryl group, hydrogen, a heteroaryl group, and a five or six member ring structure formed from the R1 and R2 pair, the R3 and R4 pair, the R4 and R5 pair, or the R5 and R6 pair; R7 is a substituted or unsubstituted aryl group; and Y is a nucleophile.
Type:
Grant
Filed:
September 2, 2011
Date of Patent:
September 4, 2012
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Andrei Laikhter, Joseph A. Walder, Mark Behlke, Mikhail Podyminogin, Yawfui Yong
Abstract: The invention relates to methods and systems for predicting or estimating the melting temperature of duplex nucleic acids, in the presence of divalent cations, particularly duplexes of oligonucleotides which may be used as, for example, but not limited to primers or probes in PCR and/or hybridization assays. The methods and algorithms use novel formulas, having terms and coefficients that are functions of the particular nucleotide sequence, to estimate the effect of divalent cation salt conditions on the melting temperature.
Type:
Application
Filed:
November 7, 2011
Publication date:
May 17, 2012
Applicant:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Richard Owczarzy, Bernardo Moreira, Yong You, Mark Aaron Behlke, Joseph Alan Walder
Abstract: The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.
Type:
Application
Filed:
September 7, 2011
Publication date:
May 3, 2012
Applicant:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Mark Aaron Behlke, Richard Owczarzy, Yong You, Joseph Alan Walder, Kim Lennox
Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.
Type:
Application
Filed:
November 17, 2011
Publication date:
March 15, 2012
Applicant:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Andrei Laikhter, Mark Aaron Behlke, Joseph Walder, Kevin William Roberts, Yawfui Yong
Abstract: The disclosed invention pertains to improved oligonucleotide manufacturing methods, including novel support compositions that are optionally labeled, their methods of preparation and use. The compositions and methods are particularly well suited for high throughput oligonucleotide manufacturing in that the automated support recognition facilitates loading of the wells with the proper supports. In addition, the labeled supports can be used to confirm that each well of a multi-well plate, such as a 96 or 384 well plate, was properly loaded.
Type:
Grant
Filed:
May 21, 2007
Date of Patent:
March 6, 2012
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Yakov A. Letuchy, William E. Martin, David W. Muller, Shawn Allen, Shawn P. Walsh
Abstract: The invention provides novel anthraquinone compositions that are useful as broad-spectrum quenchers of fluorescence and provides methods for making and using them. The anthraquinone quenchers can be conjugated to a variety of biologically relevant compounds, including lipids, nucleic acids, polypeptides, and more specifically antigens, steroids, vitamins, drugs, haptens, metabolites, toxins, environmental pollutants, amino acids, peptides, proteins, nucleotides, oligonucleotides, polynucleotides, carbohydrates, and their analogs. The invention also provides kits comprising, in one or more containers, at least one anthraquinone quencher dye composition of the present invention, and instructions for using that composition.
Type:
Grant
Filed:
August 10, 2010
Date of Patent:
February 14, 2012
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Andrei Laikhter, Mark Aaron Behlke, Yawfui Yong, Scott Rose, Lingyan Huang
Abstract: The present invention provides methods that more accurately predict melting temperatures for duplex oligomers. The invented methods predict the Tm of chimeric duplexes containing various amounts of locked nucleic acid modifications in oligonucleotide strands.
Type:
Application
Filed:
July 29, 2011
Publication date:
February 2, 2012
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Mark Behlke, Richard Owczarzy, Scott D. Rose, Andrey Tataurov, Yong You
Abstract: A compound having the general formula shown below: where R1-6 are independently selected from the group consisting of an electron withdrawing group, an alkyl group, an aryl group, hydrogen, a heteroaryl group, and a five or six member ring structure formed from the R1 and R2 pair, the R3 and R4 pair, the R4 and R5 pair, or the R5 and R6 pair; R7 is a substituted or unsubstituted aryl group; and Y is a nucleophile.
Type:
Application
Filed:
September 2, 2011
Publication date:
December 29, 2011
Applicant:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Andrei Laikhter, Joseph A. Walder, Mark Behlke, Mikhail Podyminogin, Yawfui Yong
Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.
Type:
Grant
Filed:
October 16, 2008
Date of Patent:
December 27, 2011
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Andrei Laikhter, Mark Aaron Behlke, Joseph Walder, Kevin William Roberts, Yawfui Yong
Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
Type:
Grant
Filed:
March 15, 2005
Date of Patent:
December 27, 2011
Assignees:
City of Hope, Integrated DNA Technologies, Inc.
Inventors:
John J. Rossi, Mark A. Behlke, Dongho Kim
Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
Type:
Application
Filed:
July 8, 2011
Publication date:
December 8, 2011
Applicants:
INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPE
Inventors:
John J. ROSSI, Mark A. BEHLKE, Dongho KIM
Abstract: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.
Type:
Application
Filed:
July 8, 2011
Publication date:
December 8, 2011
Applicants:
INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPE
Inventors:
John J. ROSSI, Mark A. BEHLKE, Dongho KIM